Dutch biotech using genetic suppressors for evolution-inspired rare-disease medicine.
| Date | Round | Amount |
|---|---|---|
| Apr 2022 | Series A Amsterdam biotech Scenic Biotech raised a 28M euro Series A co-led by Eir Ventures, BioMedPartners and Vesalius Biocapital, with Inkef Capital. | $28M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.